Table 2.
Patient characteristics comparing participants with cardiac dysfunction and normal function
| Characteristics | Cardiac dysfunction (N=35) |
Normal function (N=115) |
P-Value |
|---|---|---|---|
| Sex, No. (%) | |||
| Male | 16 (45.7) | 69 (60.0) | |
| Female | 19 (54.3) | 46 (40.0) | 0.19 |
| Race/Ethnicity, No. (%) | |||
| Non-Hispanic white | 12 (34.3) | 42 (36.5) | |
| Hispanic | 16 (45.7) | 57 (49.6) | |
| Other | 7 (20.0) | 16 (13.9) | 0.56 |
| Age at examination, Years (%) | |||
| ≤18 | 6 (17.1) | 28 (24.3) | |
| 19–29 | 6 (17.1) | 28 (24.3) | |
| ≥30 | 23 (65.7) | 59 (51.3) | 0.33 |
| BMI at examination | |||
| Overweight or obese** | 15 (42.8) | 51 (45.6) | 0.88 |
| Lifetime Anthracycline, mg/m2 (%) | |||
| Median, range | 400 (75–541) | 300 (25–759) | <0.01 |
| Chest radiation, No. (%) | |||
| None | 29 (82.9) | 105 (91.3) | |
| Any | 6 (17.1) | 10 (8.7) | 0.12 |
| Ejection fraction (%) | |||
| Median (Range) | 58 (50–67) | 62 (50–85) | <0.01 |
| Mean arterial pressure (MAP), mmHg | |||
| Median MAP, range | 82.7 (66–115) | 81.2 (58–135) | 0.23 |
| On anti-hypertensive medications at the time of assessment, No. (%)* | |||
| Any | 4 (11.4) | 9 (7.8) | 0.51 |
*
Defined as ≥25 Kg/m2 if ≥18 years old, or ≥85% for age if <18 years old.
**
Angiotensin converting enzyme inhibitor or beta-blocker